24 completed, 7 unknown, 3 recruiting, 2 not yet recruiting. 10 Phase 3, 8 Phase 1, 7 Phase 4, 6 Phase 2, 1 Not applicable.
Follow Butantan Institute: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya | Phase 3 | Not yet recruiting | Butantan Institute | 900 | 2027-03-31 | 2026-07-16 |
| Phase 3b Trial To Evaluate Safety And Immune Response (Superiority) of a Two-Dose Butantan-DV Regimen And The Standard Single Dose In Dengue-Naive Children/Adolescents and Immune Response (Non-inferiority) in a Manufacturing Facility Change (DEN-06-IB) Butantan-DV (IB), Butantan-DV (WuXi), Placebo - Dengue Fever With Warning Signs | Phase 3 | Not yet recruiting | Butantan Institute | 1765 | 2027-02-01 | 2026-07-20 |
| Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases Dengue 1,2,3,4 (attenuated) vaccine - Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA) | Phase 4 | Recruiting | University of Sao Paulo General Hospital | 477 | 2026-03-16 | 2026-07-20 |
| Butantan-DV Vaccine in Elderly Populations (DEN-04-IB) Dengue 1,2,3,4 (attenuated) vaccine - Dengue | Phase 3 | Recruiting | Butantan Institute | 997 | 2026-03-03 | 2026-07-16 |
| Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg, Monovalent influenza vaccine type A (H5N8) 15 mcg, Placebo - Avian Influenza A Virus | Phase 1 / Phase 2 | Recruiting | Butantan Institute | 700 | 2025-09-10 | 2026-04-02 |
| Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children . Quadrivalent Influenza Vaccine (split virion, inactivated), Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage, Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage - Influenza, Human | Phase 3 | Completed | Butantan Institute | 1373 | 2023-04-25 | 2025-09-19 |
| Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine NDV-HXP-S 10μg, BNT162b2 30μg - Coronavirus Infections, Healthy | Phase 2 / Phase 3 | Completed | Butantan Institute | 4400 | 2023-02-28 | 2025-02-06 |
| Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002) V181, Butantan - DV - Dengue | Phase 2 | Completed | Butantan Institute | 1364 | 2023-02-15 | 2025-11-18 |
| A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents Active, Placebo - Chikungunya | Phase 3 | Completed | Butantan Institute | 754 | 2022-02-14 | 2026-06-04 |
| Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents Inactivated Coronavac/Butantan vaccine, BNT162b2 (Pfizer) - COVID-19 | Phase 3 | Unknown | Federal University of Espirito Santo | 1120 | 2022-01-21 | 2022-02-04 |
| Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil NDV-HXP-S 1μg, NDV-HXP-S 3μg, NDV-HXP-S 10μg - Coronavirus Infections, Healthy | Phase 1 | Completed | Butantan Institute | 320 | 2021-07-09 | 2023-08-21 |
| Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine QIV-IB, TIVV-IB, TIVY-IB - Influenza, Human | Phase 3 | Completed | Butantan Institute | 5822 | 2021-05-12 | 2025-02-21 |
| Active Pharmacovigilance Study of Adsorbed COVID-19 (Inactivated) Vaccine Adsorbed COVID-19 (Inactivated) Vaccine - SARS-CoV-2 Acute Respiratory Disease | Completed | Butantan Institute | 2549 | 2021-05-10 | 2023-05-22 | |
| Clinical Trial to Assess Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes Streptococcus pyogenes vaccine (50 µg), Streptococcus pyogenes vaccine (100 µg), Streptococcus pyogenes vaccine (200 µg) - Rheumatic Fever | Phase 1 | Withdrawn | Butantan Institute | 2021-05-01 | 2021-02-04 | |
| Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases AntiSARS-CoV-2 Serum, Placebo - Immunosuppression, Cancer | Phase 1 / Phase 2 | Unknown | Butantan Institute | 618 | 2021-05-01 | 2021-04-08 |
| Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity Adsorbed SARS-CoV-2 (inactivated) vaccine - Covid19 | Phase 4 | Unknown | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | 6233 | 2021-03-18 | 2021-07-26 |
| A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19 Adsorbed COVID-19 (inactivated) Vaccine - COVID-19 | Phase 4 | Unknown | D'Or Institute for Research and Education | 1200 | 2021-02-19 | 2021-07-09 |
| An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine Adsorbed COVID-19 (Inactivated) Vaccine - Covid19 | Phase 4 | Completed | Butantan Institute | 27711 | 2021-02-07 | 2024-02-15 |
| Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA) COVID-19 | Completed | Butantan Institute | 3520 | 2020-10-25 | 2025-02-06 | |
| Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals Adsorbed COVID-19 (inactivated) Vaccine, Placebo - COVID-19 | Phase 3 | Completed | Butantan Institute | 12688 | 2020-07-21 | 2024-02-15 |
Showing 20 of 37. Sign in to see all of them.
Influenza, Human (12) · COVID-19 (10) · Dengue (5) · Neoplasms (3) · Chikungunya Fever (2) · Coronavirus Infections (2) · Antiphospholipid Syndrome (1) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Asymptomatic Infections (1) · Axial Spondyloarthritis (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Granulomatosis with Polyangiitis (1)
Vaccines (10) · sinovac COVID-19 vaccine (5) · Influenza Vaccines (4) · BNT162 Vaccine (2) · NDV-HXP-S COVID-19 vaccine (2) · Adjuvants, Pharmaceutic (1) · Chickenpox Vaccine (1) · Exercise (1) · Rotavirus Vaccines (1) · Serologic Tests (1) · Vaccines, Attenuated (1) · Vaccines, Inactivated (1) · hexavalent group A streptococcal vaccine (1) · monophosphoryl lipid A (1) · serogroup C meningococcal conjugate vaccine (1)
Brazil (34)
Alexander R Precioso, MD, PhD (3) · Fernanda C Boulos, MD, PhD (3) · Alexander Precioso, MD, PhD (2) · Ricardo Palacios, MD, PhD (2) · Alex R Precioso, MD, PhD (1) · Alexander R Precioso, MD,PhD (1) · Alexander Roberto Precioso, MD, PhD (1) · Daniela R Dal Fabbro, BSN (1) · Elivane S Victor, BSS (1) · Erika H Zaher, PhD (1) · Esper Kallas, PhD (1) · Expedito J Luna, MD (1) · Fernanda Boulos, MD, MSc (1) · Fernanda Boulos, MD, PhD (1)
PMID 39116904, PMID 30066805, PMID 32220283, PMID 38294972, PMID 41092804, PMID 21945258, PMID 22087267, PMID 30570077, PMID 32497524, PMID 33988337, PMID 35464483, PMID 35837409, PMID 36256646, PMID 36435633, PMID 37321235, PMID 39243794, PMID 39255380, PMID 40037239, PMID 41380703, PMID 41714650, PMID 41781546, PMID 42253092, PMID 42329996, PMID 42383822